Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (14144)	11/16/2004 4:08:41 PM
From: rkrw	Read Replies (1) \| Respond to of 52153

Prevent II data does look good across the board. Even "refuse angiography" comparison is favorable :-) Was prevent II a single site study?

To: tuck who wrote (14144)	11/16/2004 7:44:42 PM
From: Archie Meeties	Read Replies (1) \| Respond to of 52153

Angiography may be the standard, but to get at what an e2f inhibitor should do, you would either have to get the histology (most IRB's would protest) or use intravascular ultrasound. Part of the problem with angiography is that you're getting lumen size only, and not data about the changes happening in the vein. IVUS can get you both. For example, there may be massive sm hyperplasia, but lumen may remain the same because there is nothing initially restricting the growth in the diameter of the vein.